Supernus Pharmaceuticals Inc (SUPN) Stock Analysis
Verdict: WATCH (do not buy)
Qelbree-driven top-line growth is offset by operating losses and Trokendi XR patent cliff drag — keeping valuation capped near 52-week lows.
Investment score: 49/100
Analysis as of
Is Supernus Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
The model views Supernus Pharmaceuticals as a HOLD, balancing long-term product ramp-up in ADHD (Qelbree) against near-term margin compression and generic erosion of legacy drugs.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 68/100 (weight 10%)
- Risk-Adjusted Return: 48/100 (weight 15%)
Supernus Pharmaceuticals Inc opportunities and risks
What speaks for SUPN
- Qelbree market adoption in pediatric and adult ADHD
What speaks against SUPN
- Patent cliff and generic competition on legacy products
Frequently asked questions about Supernus Pharmaceuticals Inc (SUPN)
Is SUPN stock a good investment?
The TradeMates model rates Supernus Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 49/100. The model views Supernus Pharmaceuticals as a HOLD, balancing long-term product ramp-up in ADHD (Qelbree) against near-term margin compression and generic erosion of legacy drugs. This is algorithmic model output, not personal investment advice.
Is SUPN stock a buy?
The TradeMates model verdict for SUPN is WATCH (do not buy) with an investment score of 49/100. Treat this as a model signal to review, not a personal buy recommendation.